




RealRate

PHARMACEUTICAL 2014

Array Biopharma INC
Rank 180 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Array Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Array Biopharma INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 5.8% points. The greatest weakness of Array Biopharma INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is 135%, being 108% points below the market average of 243%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	121,309	Assets	135,988
Cost of Goods Sold	30,078	Liabilities	157,897
Intangible Assets	0	Expenses	131,522
Liabilities, Current	50,577	Revenues	69,580
Liabilities, Non-Current	107,320	Stockholders Equity	-21,909
Other Assets	4,630	Net Income	-61,942
Other Compr. Net Income	-1.0	Comprehensive Net Income	-61,942
Other Expenses	22,400	BaseVar	247,494
Other Liabilities	0	ECR before LimitedLiability	-75%
Other Net Income	0	Economic Capital Ratio	135%
Other Revenues	69,580		
Property and Equipment	10,049		
Research and Development	59,420		
Selling, General and Administrative Expense	19,624		